Aria Vaishnavi, Assistant Professor at MD Anderson Cancer Center, on X:

“I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer.

Here, using multiple genetic and patient-derived mouse models, we reveal that activation of BRAFV600Eoncoprotein drives transcriptional upregulation of ERBB family ligands in the AT2 cells of the lung.

This ERBB autocrine loop serves to support the initiation and maintenance of therapeutic responses in preclinical models of BRAFV600E-driven lung cancer by combined inhibition of both BRAFV600E signaling plus pan-ERBB signaling. Collectively, this work provides evidence for an important role for ERBB family signaling in BRAFV600E-driven lung cancers.”

Authors: BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling

Authors: Melanie Dacheux, Meng-Jung Wu, Michael T Scherzer, Monique Nillson, Brandon Murphy, Sophia Schuman, Zhenlin Ju, Trever Bivona, Piro Lito, Matthew Gumbleton, Sonam Puri, Wallace Akerley, Jing Wang, Kaiwen Wang, John Victor Heymach, Conan G Kinsey, Marcelo V Negrao, Martin McMahon, Aria Vaishnavi

Read Full Article.

Aria Vaishnavi

More posts about Lung Cancer on OncoDaily.

Aria Vaishnavi: First Preprint From My Lab on ERBB Signaling in BRAFV600E-Driven Lung Cancer

“I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer.

Here, using multiple genetic and patient-derived mouse models, we reveal that activation of BRAFV600Eoncoprotein drives transcriptional upregulation of ERBB family ligands in the AT2 cells of the lung.